Thanks MysteryZ, It looks like they have a better handle on the drug,,. plans to re-submit with more mature data, which allows CHMP to conclude a clear benefit/risk ratio. that line says a whole lot.. I am taking it that C has got more up to date and better information to give and is willing to take on the extra cost of resubmission to make sure that the CHMP has a clear picture and this could in turn speed up the approval process.. That is how I see it. Pilot
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.